Resalis Therapeutics srlAfter securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.
Tag Archive for: Sanofi
Resalis/VimeoItalian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
French Sanofi SAs second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
French pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli.